Literature DB >> 16040543

ICF Core Set for patients with musculoskeletal conditions in early post-acute rehabilitation facilities.

Monika Scheuringer1, Gerold Stucki, Erika Omega Huber, Mirjam Brach, Susanne R Schwarzkopf, Nenad Kostanjsek, Thomas Stoll.   

Abstract

PURPOSE: The aim of this consensus process was to decide on a first version of the ICF Core Set for patients with musculoskeletal conditions in early post-acute rehabilitation facilities.
METHODS: The ICF Core Set development involved a formal decision-making and consensus process integrating evidence gathered from preliminary studies including focus groups of health professionals, a systematic review of the literature and empiric data collection from patients.
RESULTS: Fifteen experts selected a total of 70 second-level categories. The largest number of categories was selected from the ICF component Body Functions (23 categories or 33%). Seven (10%) of the categories were selected from the component Body Structures, 22 (31%) from the component Activities and Participation, and 18 (26%) from the component Environmental Factors.
CONCLUSION: The Post-acute ICF Core Set for patients with musculoskeletal conditions is a clinical framework to comprehensively assess patients in early post-acute rehabilitation facilities, particularly in an interdisciplinary setting. This first ICF Core Set will be further tested through empiric studies in German-speaking countries and internationally.

Entities:  

Mesh:

Year:  2005        PMID: 16040543     DOI: 10.1080/09638280400014006

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  8 in total

1.  [International classification of functioning, disability and health and its significance for rheumatology].

Authors:  J Braun; J Zochling; E Grill; W Liman; G Stucki
Journal:  Z Rheumatol       Date:  2007-11       Impact factor: 1.372

2.  Developing a Core Set to describe functioning in vocational rehabilitation using the international classification of functioning, disability, and health (ICF).

Authors:  Reuben Escorpizo; Jan Ekholm; Hans-Peter Gmünder; Alarcos Cieza; Nenad Kostanjsek; Gerold Stucki
Journal:  J Occup Rehabil       Date:  2010-12

Review 3.  [Using the International Classification of Functioning, Disability, and Health in rheumatologic rehabilitation].

Authors:  M Weigl; S R Schwarzkopf; G Stucki
Journal:  Z Rheumatol       Date:  2008-11       Impact factor: 1.372

4.  Towards an ICF-based self-report questionnaire for people with skeletal dysplasia to study health, functioning, disability and accessibility.

Authors:  Heidi Anttila; Susanna Tallqvist; Minna Muñoz; Sanna Leppäjoki-Tiistola; Outi Mäkitie; Sinikka Hiekkala
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

5.  Synthesising practice guidelines for the development of community-based exercise programmes after stroke.

Authors:  Leon Poltawski; Charles Abraham; Anne Forster; Victoria A Goodwin; Cherry Kilbride; Rod S Taylor; Sarah Dean
Journal:  Implement Sci       Date:  2013-10-01       Impact factor: 7.327

6.  Development of ICF Core Sets to standardize assessment of functioning and impairment in ADHD: the path ahead.

Authors:  Sven Bölte; Elles de Schipper; Martin Holtmann; Sunil Karande; Petrus J de Vries; Melissa Selb; Rosemary Tannock
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-12-14       Impact factor: 4.785

7.  Identification of ICF categories relevant for nursing in the situation of acute and early post-acute rehabilitation.

Authors:  Martin Mueller; Christine Boldt; Eva Grill; Ralf Strobl; Gerold Stucki
Journal:  BMC Nurs       Date:  2008-02-18

8.  The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH) can measure the impairment, activity limitations and participation restriction constructs from the International Classification of Functioning, Disability and Health (ICF).

Authors:  Diane Dixon; Marie Johnston; Margaret McQueen; Charles Court-Brown
Journal:  BMC Musculoskelet Disord       Date:  2008-08-20       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.